Savić Vedran, Janić Miodrag, Lunder Mojca, Kanc Karin, Janež Andrej, Eržen Barbara, Šabovič Mišo
Department of Vascular Diseases, Ljubljana University Medical Centre, Ljubljana SI-1000, Slovenia.
Diabetes & Me, Private Diabetes Centre, Ljubljana SI-1000, Slovenia.
Exp Ther Med. 2015 Sep;10(3):1207-1211. doi: 10.3892/etm.2015.2622. Epub 2015 Jul 7.
Improvement of arterial wall (AW) characteristics decreases cardiovascular risk. In a previous study, it was observed that AW characteristics in patients with diabetes mellitus type 1 are significantly improved by short-term treatment with a low-dose combination of fluvastatin and valsartan. Additionally, a unique phenomenon of prolonged effect after treatment discontinuation was suggested. The present study tested whether repeated treatm ent after a certain period results in the same beneficial effect, th ereby advancing the hypothesis that cyclic treatment can provide a long-term improvement of AW characteristics. A total of 44 patients with diabetes mellitus type 1 that participated in the previous study were recruited. Six months after the discontinuation of the initial treatment, the same treatment with a low-dose fluvastatin (10 mg daily) and valsartan (20 mg daily) combination (n=22) or placebo (n=22) was repeated. Brachial artery flow-mediated dilation (FMD), pulse wave velocity (PWV) and carotid artery β-stiffness were measured. It was found that the beneficial effect achieved with an initial 1-month treatment was completely regained following treatment repetition: FMD improved by 50.9% (P<0.01), PWV by 5.7% (P<0.001) and β-stiffness by 9.9% (P<0.001). In addition, a gradual decline of the obtained effects was observed, reaching the level of 9.6% for FM D, 6.3% for PWV and 9.5% for β-stiffness 6 months after treatm ent discontinuation. It was observed that repetition of treatment was similarly effective as the initial intervention. The benefits achieved by treatment steadily declined with time. Combining these findings, cyclic intermittent treatment with a low-dose fluvastatin and valsartan combination is proposed as a new cardiovascular preventive strategy in patients with DM1.
改善动脉壁(AW)特征可降低心血管风险。在先前的一项研究中,观察到1型糖尿病患者通过短期服用低剂量氟伐他汀和缬沙坦组合治疗,其AW特征得到显著改善。此外,还发现了停药后效应持续延长的独特现象。本研究测试了在一定时期后重复治疗是否会产生相同的有益效果,从而推进了循环治疗可长期改善AW特征的假设。共招募了44名参与先前研究的1型糖尿病患者。在初始治疗停药6个月后,重复使用低剂量氟伐他汀(每日10毫克)和缬沙坦(每日20毫克)组合(n = 22)或安慰剂(n = 22)进行治疗。测量肱动脉血流介导的舒张功能(FMD)、脉搏波速度(PWV)和颈动脉β硬度。结果发现,重复治疗后完全恢复了初始1个月治疗所取得的有益效果:FMD提高了50.9%(P < 0.01),PWV提高了5.7%(P < 0.001),β硬度提高了9.9%(P < 0.001)。此外,观察到所获得的效果逐渐下降,在治疗停药6个月后,FMD降至9.6%,PWV降至6.3%,β硬度降至9.5%。观察到重复治疗与初始干预同样有效。治疗所取得的益处随时间稳步下降。综合这些发现,建议将低剂量氟伐他汀和缬沙坦组合的循环间歇治疗作为DM1患者的一种新的心血管预防策略。